Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0PRCGF
ADC Name
hL49_3x_Ala-ADC
Synonyms
hL49_3x_Ala ADC
   Click to Show/Hide
Organization
Seagen Inc.
Drug Status
Investigative
Indication
In total 1 Indication(s)
Melanoma [ICD11:2C30]
Investigative
Drug-to-Antibody Ratio
4
Antibody Name
hL49_3x_Ala
  Antibody Info 
Antigen Name
Melanotransferrin (MELTF)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
mp-dLAE-PABC
  Linker Info 
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 12 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Maximum inhibition efficiency (MIE) 
8
%
A2058 cells
Melanoma
Maximum inhibition efficiency (MIE) 
65
%
A-375 cells
Amelanotic melanoma
Maximum inhibition efficiency (MIE) 
72
%
SK-MEL-28 cells
Cutaneous melanoma
Maximum inhibition efficiency (MIE) 
80
%
COLO 853 cells
Cutaneous melanoma
Maximum inhibition efficiency (MIE) 
84
%
IGR-37 cells
Melanoma
Maximum inhibition efficiency (MIE) 
87
%
SK-MEL-5 cells
Cutaneous melanoma
Half Maximal Inhibitory Concentration (IC50) 
5
nM
SK-MEL-28 cells
Cutaneous melanoma
Half Maximal Inhibitory Concentration (IC50) 
6
nM
SK-MEL-5 cells
Cutaneous melanoma
Half Maximal Inhibitory Concentration (IC50) 
10
nM
COLO 853 cells
Cutaneous melanoma
Half Maximal Inhibitory Concentration (IC50) 
162
nM
IGR-37 cells
Melanoma
Half Maximal Inhibitory Concentration (IC50) 
> 2000
nM
A2058 cells
Melanoma
Half Maximal Inhibitory Concentration (IC50) 
1.32
uM
A-375 cells
Amelanotic melanoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 12 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Maximum inhibition efficiency (MIE) 8.00% Moderate CD228 expression (CD228++)
Method Description
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model Melanoma A2058 cells CVCL_1059
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Maximum inhibition efficiency (MIE) 65.00% Low CD228 expression (CD228+)
Method Description
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model Amelanotic melanoma A-375 cells CVCL_0132
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Maximum inhibition efficiency (MIE) 72.00% Positive CD228 expression (CD228+++/++)
Method Description
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model Cutaneous melanoma SK-MEL-28 cells CVCL_0526
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Maximum inhibition efficiency (MIE) 80.00% Positive CD228 expression (CD228+++/++)
Method Description
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model Cutaneous melanoma COLO 853 cells CVCL_2003
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Maximum inhibition efficiency (MIE) 84.00% Positive CD228 expression (CD228+++/++)
Method Description
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model Melanoma IGR-37 cells CVCL_2075
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Maximum inhibition efficiency (MIE) 87.00% Positive CD228 expression (CD228+++/++)
Method Description
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model Cutaneous melanoma SK-MEL-5 cells CVCL_0527
Experiment 7 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 5.00 nM Positive CD228 expression (CD228+++/++)
Method Description
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model Cutaneous melanoma SK-MEL-28 cells CVCL_0526
Experiment 8 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 6.00 nM Positive CD228 expression (CD228+++/++)
Method Description
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model Cutaneous melanoma SK-MEL-5 cells CVCL_0527
Experiment 9 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 10.00 nM Positive CD228 expression (CD228+++/++)
Method Description
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model Cutaneous melanoma COLO 853 cells CVCL_2003
Experiment 10 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 162 nM Positive CD228 expression (CD228+++/++)
Method Description
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model Melanoma IGR-37 cells CVCL_2075
Experiment 11 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 2000 nM Moderate CD228 expression (CD228++)
Method Description
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model Melanoma A2058 cells CVCL_1059
Experiment 12 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 1.32 uM Low CD228 expression (CD228+)
Method Description
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model Amelanotic melanoma A-375 cells CVCL_0132
References
Ref 1 Anti-cd228 antibodies and antibody-drug conjugates; 2022-02-10.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.